A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single-ascending Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pf-06818883 Following Single Intravenous Administration In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2017
At a glance
- Drugs PF 6818883 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Jul 2017 Status changed from suspended to discontinued.
- 24 Apr 2017 Status changed from recruiting to suspended.
- 02 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 May 2017.